HeyJaredArchita Rai
- Indexed articles, last 90 days
- 66
- Latest publication
- Aug 25, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Gout Tied to Elevated Fracture Risk; Drug Adherence Helps (opens the original)
Read excerpt
Patients with newly diagnosed gout had a higher risk for fractures than individuals without gout, but higher allopurinol adherence was associated with a relatively lower fracture risk, according to a retrospective analysis of a nationwide South Korean health insurance database. “[The] findings highlight that consistent, long-term medication adherence may be essential to reducing the possible fracture burden in gout patients,” the authors of the study wrote. The study was led by Jang Ho Doo, Seou
Bladder Issues Linger in Kids Treated for Ureter Swelling (opens the original)
Read excerpt
More than one third of children who received surgery to treat ureterocele had lower urinary tract dysfunction years later, especially after reconstructive surgery. “Patients and families should be counseled about this association and screened accordingly to minimize lower urinary tract dysfunction morbidity,” the researchers wrote. The study was led by Tyler Overholt Daniel, MD, of University of Pittsburgh Medical Center and was published online on August 13 in the Journal of Pediatric Urology.
Biologic Choice May Affect PsA Progression in Psoriasis (opens the original)
Read excerpt
Among patients with psoriasis treated with a single class of biologic disease-modifying antirheumatic drug (bDMARD), treatment with interleukin (IL)-17, IL-23, or IL-12/23 inhibitors was associated with a significantly lower risk of developing psoriatic arthritis (PsA) than treatment with TNF inhibitors. "In our real-world study, we found that both IL-23i [IL-23 inhibitors] and IL-17i [IL-17 inhibitors] offer protection from the development of PsA, in patients with psoriasis," the authors wrote.
Dual Targeted Therapy May Be Beneficial in Refractory PsA (opens the original)
Read excerpt
In a real‑world cohort of patients with treatment-refractory psoriatic arthritis (PsA), combining two advanced targeted therapies was feasible and was associated with improvements in joint and skin measures and patient‑reported outcomes. Adverse events were infrequent and mostly mild. “Dual b/tsDMARD therapy demonstrated clinically meaningful improvement with no new safety concerns, supporting its cautious, individualized use when sequential monotherapy fails,” the authors wrote. The study was l
Ustekinumab, Biosimilars Have Similar Medicare Part D Costs (opens the original)
Read excerpt
In 2026, Medicare Part D plans mostly covered the originator ustekinumab drug Stelara and several biosimilars, but patients ended up paying about the same out-of-pocket costs across products and they had little incentive to use lower gross-price options. “Plans should prioritize coverage of low gross-cost biosimilars that provide beneficiaries with lower out-of-pocket costs,” the authors wrote. The study was led by Grace Castle, Vanderbilt University, Nashville, Tennessee. It was published onlin
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.